These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29430842)

  • 1. Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes.
    Cheang JY; Moyle PM
    ChemMedChem; 2018 Apr; 13(7):662-671. PubMed ID: 29430842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albumin-binding domain extends half-life of glucagon-like peptide-1.
    Tan H; Su W; Zhang W; Zhang J; Sattler M; Zou P
    Eur J Pharmacol; 2021 Jan; 890():173650. PubMed ID: 33049303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into nanomedicines for oral delivery of glucagon-like peptide-1 analogs.
    Pinto SFT; Santos HA; Sarmento BFCC
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1952. PubMed ID: 38500351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coordinated ASBT and EGFR Mechanisms for Optimized Liraglutide Nanoformulation Absorption in the GI Tract.
    Kweon S; Park SJ; Lee HK; Kang SH; Chang KY; Choi JU; Park J; Shim JH; Park JW; Byun Y
    Int J Nanomedicine; 2024; 19():2973-2992. PubMed ID: 38544951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in the contrary effects of glucagon-like peptide-1 and chemerin on obesity development.
    Zhang Q; Ye J; Wang X
    Exp Biol Med (Maywood); 2023 Nov; 248(22):2020-2029. PubMed ID: 38058030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of recent research and development on GLP-1 receptor agonists-sustained-release microspheres.
    Gao Z; Wei Y; Ma G
    J Mater Chem B; 2023 Dec; 11(47):11184-11197. PubMed ID: 37975420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymer-based delivery of glucagon-like Peptide-1 for the treatment of diabetes.
    Kim PH; Kim SW
    ISRN Endocrinol; 2012; 2012():340632. PubMed ID: 22701182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Navigating uncharted waters: long-term implications of GLP-1 agonist use.
    Sher T; Sujka J
    Surg Obes Relat Dis; 2024 May; 20(5):499-500. PubMed ID: 38368200
    [No Abstract]   [Full Text] [Related]  

  • 9. Cold Exposure and Oral Delivery of GLP-1R Agonists by an Engineered Probiotic Yeast Strain Have Antiobesity Effects in Mice.
    Hedin KA; Zhang H; Kruse V; Rees VE; Bäckhed F; Greiner TU; Vazquez-Uribe R; Sommer MOA
    ACS Synth Biol; 2023 Nov; 12(11):3433-3442. PubMed ID: 37827516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comments on "GLP-1 agonists: A review for emergency clinicians".
    Mattingly TJ; LaFleur G; Ruble JH
    Am J Emerg Med; 2024 Jun; 80():194-196. PubMed ID: 38582620
    [No Abstract]   [Full Text] [Related]  

  • 11. In response: Considerations regarding compounding pharmacies and GLP-1 agonists.
    Long B; Pelletier J; Koyfman A; Bridwell RE
    Am J Emerg Med; 2024 Jun; 80():197-198. PubMed ID: 38600000
    [No Abstract]   [Full Text] [Related]  

  • 12. Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review.
    Bodnaruc AM; Prud'homme D; Blanchet R; Giroux I
    Nutr Metab (Lond); 2016; 13():92. PubMed ID: 27990172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
    Drucker DJ
    Cell Metab; 2018 Apr; 27(4):740-756. PubMed ID: 29617641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
    Doggrell SA
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 Receptor Expression Within the Human Heart.
    Baggio LL; Yusta B; Mulvihill EE; Cao X; Streutker CJ; Butany J; Cappola TP; Margulies KB; Drucker DJ
    Endocrinology; 2018 Apr; 159(4):1570-1584. PubMed ID: 29444223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2.
    Mulvihill EE
    Curr Opin Lipidol; 2018 Apr; 29(2):95-103. PubMed ID: 29432213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System.
    Fadini GP; Sarangdhar M; Avogaro A
    BMJ Open Diabetes Res Care; 2018; 6(1):e000475. PubMed ID: 29449951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials.
    Jia X; Alam M; Ye Y; Bajaj M; Birnbaum Y
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):65-72. PubMed ID: 29445896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide protects cardiac function in diabetic rats through the PPARα pathway.
    Zhang Q; Xiao X; Zheng J; Li M; Yu M; Ping F; Wang T; Wang X
    Biosci Rep; 2018 Feb; 38(2):. PubMed ID: 29440457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1: Molecular mechanisms and outcomes of a complex signaling system.
    Smith NK; Hackett TA; Galli A; Flynn CR
    Neurochem Int; 2019 Sep; 128():94-105. PubMed ID: 31002893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.